Skip to content

Study of the Effectiveness of Breakfast Recommendations On Reducing Body Weight

Randomized Controlled Trial of Breakfast Recommendations on Weight: A Multi-Site Effectiveness Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01781780
Enrollment
309
Registered
2013-02-01
Start date
2013-01-31
Completion date
2014-01-31
Last updated
2014-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Habits, Obesity

Keywords

Obesity, Weight Loss, Breakfast

Brief summary

This is an experiment that will compare the effect of recommending breakfast consumption, or breakfast skipping, on body weight. Our objective is to determine if breakfast consumption recommendations can produce weight loss, and if that weight loss is dependent on typical breakfast eating habits.

Interventions

BEHAVIORALGeneral Nutrition Recommendations
BEHAVIORALBreakfast Recommendation
BEHAVIORALNo Breakfast Recommendation

Sponsors

University of Copenhagen
CollaboratorOTHER
University of Colorado, Denver
CollaboratorOTHER
Boston University
CollaboratorOTHER
Columbia University
CollaboratorOTHER
David Allison, Phd
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Ages 20-65 * Men and women * BMI ≥25, and ≤45 kg/m2 * Interested in weight loss * Start day by 9:00 a.m. at least 5 days a week

Exclusion criteria

* Participation in any weight-reduction program, weight-loss diet, or other special diet within the previous 3 months. * Weight loss or gain of \>5% of body weight in the past 6 months for any reason except post-partum weight loss. * Currently taking medication that suppresses or stimulates appetite. * Currently regularly taking medication that requires eating with food in the morning as indicated on the prescription, or any non-steroidal anti-inflammatory drugs such as baby aspirin or Tylenol. * History of prior surgical procedure for weight control or liposuction. * Current smoker or quit smoking less than 6 months prior. * Any major disease, including: Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer). Active or chronic infections, including self-reported HIV positivity and active tuberculosis. Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease (e.g., coronary artery bypass, percutaneous transluminal coronary angioplasty) in the past 6 months; New York Heart Association Functional Class \>2 with respect to congestive heart failure; stroke or transient ischemic attack in the past 6 months. Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy). Active renal disease. Lung disease: chronic obstructive airway disease requiring use of oxygen. Diagnosed diabetes (type 1 or 2) and taking any anti-diabetic medications and/or controlling the disease via dietary manipulations. Uncompensated or uncontrolled psychiatric disease (such as schizophrenia and bipolar disorder) that, in opinion of the investigators, would impede conduct of the trial or completion of procedures. * A score on the Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983) that exceeds the 90th percentile. * History of or current eating disorders, or an Eating Attitudes Test (EAT-26) score \>20. * Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; another household member is a participant or staff member in the trial; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes. * Currently taking antidepressant, steroid, or thyroid medication, unless dosage has been stable for at least 6 months. * A recent or ongoing problem with drug abuse or addiction. * Excessive alcohol intake, either acute or chronic defined as any one of the following: 1) average consumption of 3 or more alcohol containing beverages daily; 2) consumption of 7 or more alcoholic beverages within a 24-hr period in the past 12 months; or 3) other evidence available to clinic staff. * Willing to be randomized to any of the three experimental conditions. * Pregnancy and childbearing: currently pregnant or less than 3 months post partum; currently nursing or within 6 weeks of having completed nursing; pregnancy anticipated during study; unwilling to report possible or confirmed pregnancies promptly during the course of the trial; unwilling to take adequate contraceptive measures if potentially fertile. * Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.

Design outcomes

Primary

MeasureTime frameDescription
Body Weight ChangeDifference between baseline, and after 16 weeksWeight will be measured in light indoor clothes without shoes. Weight measurements will be recorded to the nearest 0.1 kg using a digital scale.

Secondary

MeasureTime frameDescription
Change in Body Mass IndexDifference between baseline and after 16 weeksBMI will be calculated as kg/m2.

Countries

Denmark, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026